138 related articles for article (PubMed ID: 21761053)
1. Development of target-specific multimodality imaging agent by using hollow manganese oxide nanoparticles as a platform.
Ha TL; Kim HJ; Shin J; Im GH; Lee JW; Heo H; Yang J; Kang CM; Choe YS; Lee JH; Lee IS
Chem Commun (Camb); 2011 Aug; 47(32):9176-8. PubMed ID: 21761053
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Dual-Modality Fluorescence and Magnetic Resonance Imaging-Guided Lymph Node Mapping with Good Biocompatibility Manganese Oxide Nanoparticles.
Zhan Y; Zhan W; Li H; Xu X; Cao X; Zhu S; Liang J; Chen X
Molecules; 2017 Dec; 22(12):. PubMed ID: 29231865
[TBL] [Abstract][Full Text] [Related]
3. Urchin-shaped manganese oxide nanoparticles as pH-responsive activatable T1 contrast agents for magnetic resonance imaging.
Kim T; Cho EJ; Chae Y; Kim M; Oh A; Jin J; Lee ES; Baik H; Haam S; Suh JS; Huh YM; Lee K
Angew Chem Int Ed Engl; 2011 Nov; 50(45):10589-93. PubMed ID: 21928456
[No Abstract] [Full Text] [Related]
4. One-pot preparation of hydrophilic manganese oxide nanoparticles as T
Li J; Wu C; Hou P; Zhang M; Xu K
Biosens Bioelectron; 2018 Apr; 102():1-8. PubMed ID: 29101783
[TBL] [Abstract][Full Text] [Related]
5. L-DOPA-Coated Manganese Oxide Nanoparticles as Dual MRI Contrast Agents and Drug-Delivery Vehicles.
McDonagh BH; Singh G; Hak S; Bandyopadhyay S; Augestad IL; Peddis D; Sandvig I; Sandvig A; Glomm WR
Small; 2016 Jan; 12(3):301-6. PubMed ID: 26619158
[TBL] [Abstract][Full Text] [Related]
6. Fabrication and evaluation of tumor-targeted positive MRI contrast agent based on ultrasmall MnO nanoparticles.
Huang H; Yue T; Xu K; Golzarian J; Yu J; Huang J
Colloids Surf B Biointerfaces; 2015 Jul; 131():148-54. PubMed ID: 25982318
[TBL] [Abstract][Full Text] [Related]
7. Hollow manganese oxide nanoparticles as multifunctional agents for magnetic resonance imaging and drug delivery.
Shin J; Anisur RM; Ko MK; Im GH; Lee JH; Lee IS
Angew Chem Int Ed Engl; 2009; 48(2):321-4. PubMed ID: 19040234
[No Abstract] [Full Text] [Related]
8. Structure-property relationships in manganese oxide--mesoporous silica nanoparticles used for T1-weighted MRI and simultaneous anti-cancer drug delivery.
Chen Y; Chen H; Zhang S; Chen F; Sun S; He Q; Ma M; Wang X; Wu H; Zhang L; Zhang L; Shi J
Biomaterials; 2012 Mar; 33(7):2388-98. PubMed ID: 22177841
[TBL] [Abstract][Full Text] [Related]
9. Manganese Oxide Nanoparticles As MRI Contrast Agents In Tumor Multimodal Imaging And Therapy.
Cai X; Zhu Q; Zeng Y; Zeng Q; Chen X; Zhan Y
Int J Nanomedicine; 2019; 14():8321-8344. PubMed ID: 31695370
[TBL] [Abstract][Full Text] [Related]
10. Manganese oxide-based multifunctionalized mesoporous silica nanoparticles for pH-responsive MRI, ultrasonography and circumvention of MDR in cancer cells.
Chen Y; Yin Q; Ji X; Zhang S; Chen H; Zheng Y; Sun Y; Qu H; Wang Z; Li Y; Wang X; Zhang K; Zhang L; Shi J
Biomaterials; 2012 Oct; 33(29):7126-37. PubMed ID: 22789722
[TBL] [Abstract][Full Text] [Related]
11. Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging.
Bae KH; Lee K; Kim C; Park TG
Biomaterials; 2011 Jan; 32(1):176-84. PubMed ID: 20934746
[TBL] [Abstract][Full Text] [Related]
12. Development of a T1 contrast agent for magnetic resonance imaging using MnO nanoparticles.
Na HB; Lee JH; An K; Park YI; Park M; Lee IS; Nam DH; Kim ST; Kim SH; Kim SW; Lim KH; Kim KS; Kim SO; Hyeon T
Angew Chem Int Ed Engl; 2007; 46(28):5397-401. PubMed ID: 17357103
[No Abstract] [Full Text] [Related]
13. Fabrication of MnxFe1-xO colloidal solid solution as a dual magnetic-resonance-contrast agent.
Choi D; Han A; Park JP; Kim JK; Lee JH; Kim TH; Kim SW
Small; 2009 Mar; 5(5):571-3. PubMed ID: 19089842
[No Abstract] [Full Text] [Related]
14. Mesoporous silica-coated hollow manganese oxide nanoparticles as positive T1 contrast agents for labeling and MRI tracking of adipose-derived mesenchymal stem cells.
Kim T; Momin E; Choi J; Yuan K; Zaidi H; Kim J; Park M; Lee N; McMahon MT; Quinones-Hinojosa A; Bulte JW; Hyeon T; Gilad AA
J Am Chem Soc; 2011 Mar; 133(9):2955-61. PubMed ID: 21314118
[TBL] [Abstract][Full Text] [Related]
15. Magnetic nanoparticles as contrast agents in biomedical imaging: recent advances in iron- and manganese-based magnetic nanoparticles.
Felton C; Karmakar A; Gartia Y; Ramidi P; Biris AS; Ghosh A
Drug Metab Rev; 2014 May; 46(2):142-54. PubMed ID: 24754519
[TBL] [Abstract][Full Text] [Related]
16. Improving the sensitivity of
Yang L; Wang L; Huang G; Zhang X; Chen L; Li A; Gao J; Zhou Z; Su L; Yang H; Song J
Theranostics; 2021; 11(14):6966-6982. PubMed ID: 34093865
[No Abstract] [Full Text] [Related]
17. The cell labeling efficacy, cytotoxicity and relaxivity of copper-activated MRI/PET imaging contrast agents.
Patel D; Kell A; Simard B; Xiang B; Lin HY; Tian G
Biomaterials; 2011 Feb; 32(4):1167-76. PubMed ID: 21035183
[TBL] [Abstract][Full Text] [Related]
18. The characteristics of sub 10 nm manganese oxide T1 contrast agents of different nanostructured morphologies.
Huang CC; Khu NH; Yeh CS
Biomaterials; 2010 May; 31(14):4073-8. PubMed ID: 20149451
[TBL] [Abstract][Full Text] [Related]
19. Composition-property relationships in multifunctional hollow mesoporous carbon nanosystems for PH-responsive magnetic resonance imaging and on-demand drug release.
Zhang S; Qian X; Zhang L; Peng W; Chen Y
Nanoscale; 2015 May; 7(17):7632-43. PubMed ID: 25785502
[TBL] [Abstract][Full Text] [Related]
20. FePt@MnO-Based Nanotheranostic Platform with Acidity-Triggered Dual-Ions Release for Enhanced MR Imaging-Guided Ferroptosis Chemodynamic Therapy.
Yang B; Liu Q; Yao X; Zhang D; Dai Z; Cui P; Zhang G; Zheng X; Yu D
ACS Appl Mater Interfaces; 2019 Oct; 11(42):38395-38404. PubMed ID: 31554396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
